Institution
Beaumont Health
Nonprofit•Royal Oak, Michigan, United States•
About: Beaumont Health is a nonprofit organization based out in Royal Oak, Michigan, United States. It is known for research contribution in the topics: Medicine & Population. The organization has 1483 authors who have published 1448 publications receiving 15407 citations. The organization is also known as: William Beaumont Health System & Beaumont Hospitals.
Topics: Medicine, Population, Cancer, Breast cancer, Arthroplasty
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Episode payments were higher for TAVR, despite shorter length of stay, and center SAVR volume was inversely associated with payments, which will be increasingly important to address value-based reimbursement in valve replacement surgery.
15 citations
••
TL;DR: Despite well-established aortic diameter threshold guidelines, marked variation exists both at the hospital level and in terms of the physician's rationale for the management of elective AAA repairs, demonstrating the challenge of providing uniform care for patients with AAAs despite established guidelines.
15 citations
••
TL;DR: The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination.
Abstract: The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to provide effective blood pressure control while minimizing side effects and reducing exposure to high doses of individual medications. In addition, combination therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs), have the added benefit of reducing cardiovascular mortality and morbidity over other dual therapies while providing equivalent blood pressure control. It is possible that angiotensin receptor blockers (ARBs), which unlike ACE inhibitors are minimally affected by upregulation of alternative pathways for angiotensin II accumulation following long-term treatment, would also provide such outcome benefits. At issue, however, is maintaining patient compliance, as adding medications is known to reduce adherence to treatment regimens. The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination. The areas where long-term data are lacking, notably clinical information regarding minorities and women, will also be discussed.
15 citations
••
TL;DR: In the largest contemporary US cohort reported to date, most patients undergoing diagnostic catheterization before noncardiac surgery are asymptomatic, and although randomized clinical trials have found no benefit in outcomes, revascularization is recommended in nearly half of these patients.
Abstract: Importance Many patients undergo cardiac catheterization and/or percutaneous coronary intervention (PCI) before noncardiac surgery even though these procedures are not routinely indicated. Data on this cohort of patients are limited. Objective To describe the characteristics, angiographic findings, and treatment patterns of clinically stable patients undergoing cardiac catheterization and/or PCI before noncardiac surgery in a large national registry. Design, Setting, and Participants This study is a retrospective, descriptive analysis of National Cardiac Data Registry CathPCI Registry diagnostic catheterization and PCI data from July 1, 2009, through December 31, 2014. Data analysis was performed from April 21, 2015, to January 4, 2016. The study included 194 444 patients from 1046 sites who underwent coronary angiography before noncardiac surgery. Patients with acute coronary syndrome, cardiogenic shock, cardiac arrest, or emergency catheterization were excluded. Main Outcomes and Measures Demographic characteristics, preprocedure noninvasive testing results, angiographic findings, and treatment recommendations are summarized. Among the 27 838 patients who underwent PCI, procedural details, inpatient outcomes, and discharge medications are reported. Results Of the 194 444 included patients, 113 590 (58.4%) were male, the median age was 65 years (interquartile range, 57-73 years), and 162 532 (83.6%) were white. Most were overweight or obese (152 849 [78.6%]), and 78 847 (40.6%) had diabetes mellitus. Most patients were asymptomatic (117 821 [60.6%]), although 112 302 (57.8%) had been taking antianginal medications within 2 weeks of the procedure. Prior noninvasive stress testing was reported in 126 766 (65.2%), and results were positive in 109 458 (86.3%) of those with stress data. Obstructive disease was present in 93 447 (48.1%). After diagnostic angiography, revascularization with PCI or bypass surgery was recommended in 46 380 patients (23.8%) in the overall cohort, 27 191 asymptomatic patients (23.1%), and 45 083 patients with obstructive disease (48.3%). In the 27 191 patients undergoing PCI, 367 treated lesions (1.3%) were in the left main artery and 3831 (13.8%) in the proximal left anterior descending artery. A total of 11 366 patients (40.8%) received drug-eluting stents. Complications occurred in a few patients, with a catheterization-related mortality rate of 0.05%. Conclusions and Relevance In the largest contemporary US cohort reported to date, most patients undergoing diagnostic catheterization before noncardiac surgery are asymptomatic. The discovery of obstructive coronary artery disease is common, and although randomized clinical trials have found no benefit in outcomes, revascularization is recommended in nearly half of these patients. The overall findings highlight management patterns in this population and the need for greater evidence-based guidelines and practices.
15 citations
••
TL;DR: One-way sensitivity analyses of the results found brachytherapy boost to be cost-effective over a wide range of cost, utility, and cancer progression rate assumptions.
15 citations
Authors
Showing all 1494 results
Name | H-index | Papers | Citations |
---|---|---|---|
Barry P. Rosen | 102 | 529 | 36258 |
Praveen Kumar | 88 | 1339 | 35718 |
George S. Wilson | 88 | 716 | 33034 |
Ahmed Ali | 61 | 728 | 15197 |
Di Yan | 61 | 295 | 11437 |
David P. Wood | 59 | 243 | 12154 |
Brian D. Kavanagh | 58 | 322 | 15865 |
James A. Goldstein | 49 | 193 | 12312 |
Kenneth M. Peters | 46 | 197 | 6513 |
James M. Robbins | 45 | 157 | 8489 |
Bin Nan | 44 | 139 | 5321 |
Inga S. Grills | 43 | 217 | 6343 |
Sachin Kheterpal | 43 | 169 | 8545 |
Craig W. Stevens | 42 | 164 | 6598 |
Thomas Guerrero | 41 | 93 | 5018 |